Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes

R. Knobler; M. Geroldinger-Simić; A. Kreuter; N. Hunzelmann; P. Moinzadeh; F. Rongioletti; C. P. Denton; L. Mouthon; M. Cutolo; V. Smith; A. Gabrielli; M. Bagot; A. B. Olesen; I. Foeldvari; A. Jalili; V. Kähäri; S. Kárpáti; K. Kofoed; M. Olszewska; J. Panelius; P. Quaglino; J. Seneschal; M. Sticherling; C. Sunderkötter; A. Tanew; P. Wolf; M. Worm; A. Skrok; L. Rudnicka; T. Krieg

doi:10.1111/jdv.19912

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes

R. Knobler^*
, M. Geroldinger-Simić
, A. Kreuter
, N. Hunzelmann
, P. Moinzadeh
, F. Rongioletti
, C. P. Denton
, L. Mouthon
, M. Cutolo
, V. Smith
, A. Gabrielli
, M. Bagot
, A. B. Olesen
, I. Foeldvari
, A. Jalili
, V. Kähäri
, S. Kárpáti
, K. Kofoed
, M. Olszewska
, J. Panelius

P. Quaglino, J. Seneschal, M. Sticherling, C. Sunderkötter, A. Tanew, P. Wolf, M. Worm, A. Skrok, L. Rudnicka, T. Krieg

^*Corresponding author for this work

Research output: Journal article (peer-reviewed) › Journal article

27 Citations (Scopus)

Abstract

The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes.

Original language	English
Pages (from-to)	1251-1280
Number of pages	30
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	38
Issue number	7
DOIs	https://doi.org/10.1111/jdv.19912
Publication status	Published - Jul 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Dermatology
Infectious Diseases

Access to Document

10.1111/jdv.19912

Cite this

Knobler, R., Geroldinger-Simić, M., Kreuter, A., Hunzelmann, N., Moinzadeh, P., Rongioletti, F., Denton, C. P., Mouthon, L., Cutolo, M., Smith, V., Gabrielli, A., Bagot, M., Olesen, A. B., Foeldvari, I., Jalili, A., Kähäri, V., Kárpáti, S., Kofoed, K., Olszewska, M., ... Krieg, T. (2024). Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 38(7), 1251-1280. https://doi.org/10.1111/jdv.19912

@article{f69611a9683b4efea1157289132a2dc9,

title = "Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes",

abstract = "The term {\textquoteleft}sclerosing diseases of the skin{\textquoteright} comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes.",

author = "R. Knobler and M. Geroldinger-Simi{\'c} and A. Kreuter and N. Hunzelmann and P. Moinzadeh and F. Rongioletti and Denton, \{C. P.\} and L. Mouthon and M. Cutolo and V. Smith and A. Gabrielli and M. Bagot and Olesen, \{A. B.\} and I. Foeldvari and A. Jalili and V. K{\"a}h{\"a}ri and S. K{\'a}rp{\'a}ti and K. Kofoed and M. Olszewska and J. Panelius and P. Quaglino and J. Seneschal and M. Sticherling and C. Sunderk{\"o}tter and A. Tanew and P. Wolf and M. Worm and A. Skrok and L. Rudnicka and T. Krieg",

note = "Publisher Copyright: {\textcopyright} 2024 European Academy of Dermatology and Venereology.",

year = "2024",

month = jul,

doi = "10.1111/jdv.19912",

language = "English",

volume = "38",

pages = "1251--1280",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

Knobler, R, Geroldinger-Simić, M, Kreuter, A, Hunzelmann, N, Moinzadeh, P, Rongioletti, F, Denton, CP, Mouthon, L, Cutolo, M, Smith, V, Gabrielli, A, Bagot, M, Olesen, AB, Foeldvari, I, Jalili, A, Kähäri, V, Kárpáti, S, Kofoed, K, Olszewska, M, Panelius, J, Quaglino, P, Seneschal, J, Sticherling, M, Sunderkötter, C, Tanew, A, Wolf, P, Worm, M, Skrok, A, Rudnicka, L & Krieg, T 2024, 'Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes', Journal of the European Academy of Dermatology and Venereology, vol. 38, no. 7, pp. 1251-1280. https://doi.org/10.1111/jdv.19912

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. / Knobler, R.; Geroldinger-Simić, M.; Kreuter, A. et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 38, No. 7, 07.2024, p. 1251-1280.

Research output: Journal article (peer-reviewed) › Journal article

TY - JOUR

T1 - Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1

T2 - Localized scleroderma, systemic sclerosis and overlap syndromes

AU - Knobler, R.

AU - Geroldinger-Simić, M.

AU - Kreuter, A.

AU - Hunzelmann, N.

AU - Moinzadeh, P.

AU - Rongioletti, F.

AU - Denton, C. P.

AU - Mouthon, L.

AU - Cutolo, M.

AU - Smith, V.

AU - Gabrielli, A.

AU - Bagot, M.

AU - Olesen, A. B.

AU - Foeldvari, I.

AU - Jalili, A.

AU - Kähäri, V.

AU - Kárpáti, S.

AU - Kofoed, K.

AU - Olszewska, M.

AU - Panelius, J.

AU - Quaglino, P.

AU - Seneschal, J.

AU - Sticherling, M.

AU - Sunderkötter, C.

AU - Tanew, A.

AU - Wolf, P.

AU - Worm, M.

AU - Skrok, A.

AU - Rudnicka, L.

AU - Krieg, T.

PY - 2024/7

Y1 - 2024/7

N2 - The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes.

AB - The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this consensus provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes.

UR - https://www.scopus.com/pages/publications/85187903126

U2 - 10.1111/jdv.19912

DO - 10.1111/jdv.19912

M3 - Journal article

C2 - 38456584

AN - SCOPUS:85187903126

SN - 0926-9959

VL - 38

SP - 1251

EP - 1280

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this